Amphiphysin, a synaptic vesicle protein, is an auto-immune target in rare cases of paraneoplastic neurological disorders. We report two additional cases with distinct neurological syndromes and paraneoplastic anti-amphiphysin antibodies. The first patient, a 59-year-old man, presented with cerebellar and cranial nerve dysfunction and small cell lung carcinoma. The second, a 77-year- old woman, presented with left brachial plexopathy followed by sensorimotor neuropathy and breast carcinoma.

Folli F, Solimena M, Cofiell R, Austoni M, Tallini G, Fassetta J, Bates D, Cartlidge N, Bottazzo GF, Piccolo G, De Camilli P: Autoantibodies to a 128-kD synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993;328:546–551.
Grimaldi LME, Martino G, Quattrini A, Furlan R, Bosi E, Comi G: Heterogeneity of autoantibodies in stiff-man syndrome. Ann Neurol 1993;34:57–64.
David C, Solimena M, De Camilli P: Autoimmunity in stiff-man syndrome with breast cancer is targeted to the C-terminal region of human amphiphysin, a protein similar to the yeast proteins, Rvs167 and Rvs161. FEBS Lett 1994;351:73–79.
Dropcho EJ: Anti-amphiphysin antibodies with small cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol 1996;39:659–667.
Saiz A, Dalmau J, Husta Butler M, Chen Q, Delattre JY, De Camilli P, Graus F: Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry 1999;66:214–217.
Antoine JC, Absi L, Honnorat J, Boulesteix, de Brouker T, Vial C, Butler M, De Camilli P, Michel D: Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol 1999;56:172–177.
Dorresteijn LDA, Kappelle AC, Renier WO, Gijtenbeek JMM: Anti-amphiphysin associated limbic encephalitis: a paraneoplastic presentation of a small-cell lung carcinoma. J Neurol 2002;249:1307–1308.
Georgian-Smith D, Ellis GK, Kraft GH: Amphiphysin paraneoplastic syndrome: a delayed diagnosis of breast carcinoma. Breast J 2003;9:316–318.
Erro ME, Martinez M, Ayuso T, Iragui MI: Paraneoplastic polyneuropathy with anti-amphiphysin antibodies. An Sist Sanit Navar 2004;27:103–106.
Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, Kim KK, Kilimann MW, Lennon VA: Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005;58:96–107.
Pittock SJ, Kryzer TJ, Lennon VA: Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004;56:715–719.
Thompson RJ: Studies on RNA synthesis in two populations of nuclei from the mammalian cerebral cortex. J Neurochem 1973;21:19–40.
Pieret F, Sindic CJM, Chalon MP, et al: The anti-Hu syndrome: a clinical and immunological study of 7 cases. Acta Neurol Belg 1996;96:108–116.
Petzold GC, Marcucci M, Butler MH, van Landeghem FKH, Einhäupl KM, Solimena M, Valdueza JM, De Camili P: Rhabdomyolysis and paraneoplastic stiff-man syndrome with amphiphysin autoimmunity. Ann Neurol 2004;55:286–290.
Camdessanché JP, Antoine JC, Honnorat J, Vial C, Petiot P, Convers P, Michel D: Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. Brain 2002;125:166–175.
Eggers C, Hagel C, Pfeiffer G: Anti-Hu-associated paraneoplastic sensory neuropathy with peripheral nerve demyelination and microvasculitis. J Neurol Sci 1998;155:178–181.
Sommer C, Weishaupt A, Brinkhoff J, Biko L, Wessig C, Gold R, Toyka KV: Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 2005;365:1406–1411.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.